The UK and US have forged a major bilateral deal that will guarantee no duties on UK drug shipments being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these vital products will be held at nothing for a period of 36 months.
This deal is in response to earlier statements to significantly raise duties on patented drug products, with potential rates floated up to double the cost.
"This deal with the UK bolsters the global environment for new treatments and introduces long-overdue balance to U.S.–U.K. drug exports," a release said.
Commercial Impact
Drugs constitute one of the the United Kingdom's most significant exports to the America, which is easily the primary market for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months leading up to last September, the UK sold medicines worth over eleven billion pounds to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This guarantee secures work, increases funding and paves the way for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several key commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double total health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments topped twenty percent.
Recent Tensions
This agreement follows a ongoing dispute between the sector and the British authorities over spending levels and regulatory access.
This friction were heightened by arguments that American consumers were charged several times more for the identical medicines than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
